This is a working overview of c-Met receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-17 and is reviewed periodically as new material appears.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
==== Coral bleaching ==== The Pacific Marine Environmental Laboratory attributes the first large-scale coral bleaching event in 1997–1998 to the warming waters of the concurrent El Niño event with possible contribution from anthropogenic climate change. Most critically, global mass bleaching events were recorded in 1997–98 and 2015–16, when around 75–99% losses of live coral were registered across the world. Considerable attention was also given to the collapse of Peruvian and Chilean anchovy populations that led to a severe fishery crisis following the ENSO events in 1972–73, 1982–83, 1997–98 and, more recently, in 2015–16. In particular, increased surface seawater temperatures in 1982-83 also lead to the probable extinction of two hydrocoral species in Panamá, and to a massive mortality of kelp beds along 600 km of coastline in Chile, from which kelps and associated biodiversity slowly recovered in the most affected areas even after 20 years. All these findings enlarge the role of ENSO events as a strong climatic force driving ecological changes all around the world – particularly in tropical forests and coral reefs.
A relatively short-range dating technique is based on the decay of uranium-234 into thorium-230, a substance with a half-life of about 80,000 years. It is accompanied by a sister process, in which uranium-235 decays into protactinium-231, which has a half-life of 32,760 years. While uranium is water-soluble, thorium and protactinium are not, and so they are selectively precipitated into ocean-floor sediments, from which their ratios are measured. The scheme has a range of several hundred thousand years. A related method is ionium–thorium dating, which measures the ratio of ionium (thorium-230) to thorium-232 in ocean sediment.
=== Antifungal activity === Lactoferrin and lactoferricin inhibit in vitro growth of Trichophyton mentagrophytes, which are responsible for several skin diseases such as ringworm. Lactoferrin also acts against the Candida albicans – a diploid fungus (a form of yeast) that causes opportunistic oral and genital infections in humans. Fluconazole has long been used against Candida albicans, which resulted in emergence of strains resistant to this drug. However, a combination of lactoferrin with fluconazole can act against fluconazole-resistant strains of Candida albicans as well as other types of Candida: C. glabrata, C. krusei, C. parapsilosis and C. tropicalis. Antifungal activity is observed for sequential incubation of Candida with lactoferrin and then with fluconazole, but not vice versa. The antifungal activity of lactoferricin exceeds that of lactoferrin. In particular, synthetic peptide 1–11 lactoferricin shows much greater activity against Candida albicans than native lactoferricin. Administration of lactoferrin through drinking water to mice with weakened immune systems and symptoms of aphthous ulcer reduced the number of Candida albicans strains in the mouth and the size of the damaged areas in the tongue. Oral administration of lactoferrin to animals also reduced the number of pathogenic organisms in the tissues close to the gastrointestinal tract. Candida albicans could also be completely eradicated with a mixture containing lactoferrin, lysozyme and itraconazole in HIV-positive patients who were resistant to other antifungal drugs.
Upon activation, bAREs ADP-ribosylate any number of eukaryotic proteins; such mechanism is crucial to the instigation of the diseased states associated with ADP-ribosylation. GTP-binding proteins, in particular, are well-established in bAREs pathophysiology. For examples, cholera and heat-labile enterotoxin target the α-subunit of Gs of heterotrimeric GTP-binding proteins. As the α-subunit is ADP-ribosylated, it is permanently in an "active", GTP-bound state; subsequent activation of intracellular cyclic AMP stimulates the release of fluid and ions from intestinal epithelial cells. Furthermore, C. Botulinum C3 ADP-ribosylates GTP-binding proteins Rho and Ras, and Pertussis toxin ADP-ribosylates Gi, Go, and Gt. Diphtheria toxin ADP-ribosylates ribosomal elongation factor EF-2, which attenuates protein synthesis. There are a variety of bacteria which employ bAREs in infection: CARDS toxin of Mycoplasma pneumoniae, cholera toxin of Vibrio cholerae; heat-labile enterotoxin of E. coli; exotoxin A of Pseudomonas aeruginosa; pertussis toxin of B. pertussis; C3 toxin of C. botulinum; and diphtheria toxin of Corynebacterium diphtheriae.
Sources: en.wikipedia.org
=== Available forms === Levothyroxine for systemic administration is available as an oral tablet, an intramuscular injection, and as a solution for intravenous infusion. Furthermore, it is available as both brand-name and generic products. While the FDA approved the use of generic levothyroxine for brand-name levothyroxine in 2004, the decision was met with disagreement by several medical associations. The American Association of Clinical Endocrinologists (AACE), the Endocrine Society, and the American Thyroid Association did not agree with the FDA that brand-name and generic formulations of levothyroxine were bioequivalent. As such, people were recommended to be started and kept on either brand-name or generic levothyroxine formulations and not changed back and forth from one to the other. For people who do switch products, their TSH and free T4 levels should be tested after six weeks to check that they are within the normal range. Brand names include Eltroxin, Euthyrox, Eutirox, Letrox, Levaxin, Lévothyrox, Levoxyl, L-thyroxine, Thyrax, and Thyrax Duotab in Europe; Thyrox and Thyronorm in South Asia; Euthyrox, Levoxyl, Synthroid, Tirosint, and Unithroid in North and South America; and Thyrin and Thyrolar in Bangladesh. Numerous generic versions also are available.
==== Cannabis effectively outlawed, prescription drugs ==== With the passage of the Marihuana Tax Act of 1937, federal law reflected state law – by 1936, the non-medical use of cannabis had been banned in every state. That year, the first two arrests for tax non-payment under the act, for possession of a quarter-ounce (7g), and trafficking of four pounds (1.8 kg), resulted in sentences of nearly 18 months and four years respectively. The American Medical Association (AMA) had opposed the tax act on grounds that it unduly affected the medical use of cannabis. The AMA's legislative counsel, a physician, testified that the claims about cannabis addiction, violence and overdoses were not supported by evidence. Scholars have posited that the act was orchestrated by powerful business interests – Andrew Mellon, Randolph Hearst, and the Du Pont family – to head off cheap competition to pulp and timber and plastics from the hemp industry. After the act, cannabis research and medical testing became rare. In 1939, New York City Mayor Fiorello LaGuardia, an opponent of the Marihuana Tax Act, formed the LaGuardia Committee to conduct the first US in-depth study of cannabis use. The report, produced by the New York Academy of Medicine and released in 1944, systematically contradicted government claims, finding that cannabis is not physically addictive, and its use does not lead to using other drugs or to crime. The FBN's Anslinger branded the study "unscientific", denounced all involved, and disrupted other cannabis studies at the time.
==== X-ray spectroscopy ==== X-ray spectroscopy methods can be used for genuine operando analyses of catalysts and other functional materials. The redox dynamics of sulfur with Ni/GDC anode during solid oxide fuel cell (SOFC) operation at mid- and low-range temperatures in an operando S K-edge XANES have been studied. Ni is a typical catalyst material for the anode in high temperature SOFCs. The operando spectro-electrochemical cell for this high temperature gas-solid reaction study under electrochemical conditions was based on a typical high temperature heterogeneous catalysis cell, which was further equipped with electric terminals. Very early method development for operando studies on PEM-FC fuel cells was done by Haubold et al. at Forschungszentrum Jülich and HASYLAB. Specifically they developed plexiglas spectro-electrochemical cells for XANES, EXAFS and SAXS and ASAXS studies with control of the electrochemical potential of the fuel cell. Under operation of the fuel cell they determined the change of the particle size of and oxidation state and shell formation of the platinum electrocatalyst. In contrast to the SOFC operation conditions, this was a PEM-FC study in liquid environment under ambient temperature. The same operando method is applied to battery research and yields information on the changes of the oxidation state of electrochemically active elements in a cathode such as Mn via XANES, information on coronation shell and bond length via EXAFS, and information on microstructure changes during battery operation via ASAXS.
Sources: en.wikipedia.org
==== Citrate reduction ==== An early, and very common, method for synthesizing silver nanoparticles is citrate reduction. This method was first recorded by M. C. Lea, who successfully produced a citrate-stabilized silver colloid in 1889. Citrate reduction involves the reduction of a silver source particle, usually AgNO3 or AgClO4, to colloidal silver using trisodium citrate, Na3C6H5O7. The synthesis is usually performed at an elevated temperature (~100 °C) to maximize the monodispersity (uniformity in both size and shape) of the particle. In this method, the citrate ion traditionally acts as both the reducing agent and the capping ligand, making it a useful process for AgNP production due to its relative ease and short reaction time. However, the silver particles formed may exhibit broad size distributions and form several different particle geometries simultaneously. The addition of stronger reducing agents to the reaction is often used to synthesize particles of a more uniform size and shape.
=== Artificial satellite development === In 1955, with both the United States and the Soviet Union building ballistic missiles that could be used to launch objects into space, the stage was set for nationalistic competition. On July 29, 1955, James C. Hagerty, President Dwight D. Eisenhower's press secretary, announced that the United States intended to launch "small Earth circling satellites" between July 1, 1957, and December 31, 1958, as part of the US contribution to the International Geophysical Year (IGY). On August 2, at the Sixth Congress of the International Astronautical Federation in Copenhagen, scientist Leonid I. Sedov told international reporters at the Soviet embassy of his country's intention to launch a satellite as well, in the "near future".
In Pakistan, all sexual activity outside of marriage is illegal. The punishment for sex outside marriage (zina) ranges from up to five years' imprisonment for minors to 100 lashes for unmarried adults and stoning to death for married adults, depending on marital status, age, sanity, and whether strict evidentiary requirements for a hadd punishment—such as four adult male Muslim witnesses or a confession—are met; however, no one has been stoned to death under the law to date. Male homosexuality is illegal in Pakistan and is punishable by up to ten years in prison, corporal punishment such as whipping, and, under Islamic law since 1990, potentially even stoning. Honour killings, locally referred to as karo-kari in parts of Pakistan, involve the killing of women and, less frequently, men by family or community members over alleged extramarital relationships or perceived violations of honour. Human rights organisations report that hundreds of women are killed each year, with many cases unreported. Pakistan also has a high number of reported acid attacks, with about 200 incidents annually as of 2023, most victims being women. According to Masarrat Misbah, founder of the Depilex Smileagain Foundation, women have been targeted for rejecting marriage proposals, giving birth to daughters instead of sons, or insufficient dowry. The 2011 Acid and Burn Crime Bill criminalised acid attacks, making them punishable by lengthy imprisonment and fines. In parts of Pakistan, girls are given in marriage to settle disputes or crimes between families in a customary practice called Vani.
Pharmacology is often studied by focusing on specific systems, such as endogenous neurotransmitter systems. The major systems studied in pharmacology can be categorized by their ligands and their receptors which include, but are not limited to, acetylcholine (ACh), adenosine, adrenaline, anandamide, aspartate, glutamate, glycine, purines, substance P, eicosanoids, GABA, dopamine (DA), histamine, serotonin (5-HT), serine, cannabinoids, opioids, melatonin, vasopressin (ADH), and norepinephrine (NE). Molecular targets in pharmacology include receptors, enzymes, and membrane transport proteins. Enzymes can be targeted with enzyme inhibitors. Receptors are typically categorized based on structure and function. Major receptor types studied in pharmacology include G protein coupled receptors, ligand gated ion channels, and receptor tyrosine kinases. Network pharmacology is a subfield of pharmacology that combines principles from pharmacology, systems biology, and network analysis to study the complex interactions between drugs and targets (receptors or enzymes etc.) in biological systems. The topology of a biochemical reaction network determines the shape of drug dose-response curve as well as the type of drug-drug interactions, thus can help designing efficient and safe therapeutic strategies. The topology Network pharmacology utilizes computational tools and network analysis algorithms to identify drug targets, predict drug-drug interactions, elucidate signaling pathways, and explore the polypharmacology of drugs.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.